Compare ASMB & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | BWAY |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 450.8M |
| IPO Year | 2010 | 2019 |
| Metric | ASMB | BWAY |
|---|---|---|
| Price | $26.22 | $23.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $43.40 | $26.50 |
| AVG Volume (30 Days) | ★ 98.7K | 95.6K |
| Earning Date | 03-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | $37,191,000.00 | ★ $49,094,000.00 |
| Revenue This Year | $33.33 | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $72.71 |
| Revenue Growth | ★ 31.30 | 27.08 |
| 52 Week Low | $7.75 | $7.84 |
| 52 Week High | $39.71 | $25.65 |
| Indicator | ASMB | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 53.26 |
| Support Level | $25.47 | $22.50 |
| Resistance Level | $27.50 | $24.15 |
| Average True Range (ATR) | 1.75 | 1.46 |
| MACD | 0.23 | -0.22 |
| Stochastic Oscillator | 35.04 | 49.91 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.